The $3.4 Billion Lesson Pharma Faces in Shelved Drugs
Thousands of shelved drug candidates could unlock therapies for rare diseases, but funding and partnerships lag. The ...
Students can earn while studying with these work from home opportunities designed for flexibility and academic success.
15,783 articlesThousands of shelved drug candidates could unlock therapies for rare diseases, but funding and partnerships lag. The ...
Thinking long term? These two soaring stocks offer compelling growth potential for the next 20 years. Learn how to in...
JPMorgan's revised target to $134 underscores a brighter backdrop for Bunge as the Viterra deal closes and 2026 biofu...
When Nasdaq and S&P 500 slip together into correction territory, investors face questions and tough choices. This gui...
BigBear.AI delivers a stronger Q1 2026, expanding margins and backlog while signaling a ramp in defense contracts. Th...
Biotech earnings season shines a spotlight on Delcath Systems. This guide breaks down the 2026 earnings outlook, key ...
MONECO Advisors recently boosted its stake in a defined-maturity bond ETF, signaling a deliberate ladder strategy. Le...
As AI reshapes markets, Palantir’s unique software moat could ignite a new chapter in growth. This guide compares Pal...
Cerebras just pulled biggest IPO momentum sent shockwaves through tech stocks. This article breaks down what that imp...
A suburban couple funds $80,000 into a donor-advised fund in 2026, capturing a decade of deductions at once and grant...
As markets heat up this summer, here's this tech stock stands out for its AI-focused growth story, solid finances, an...
Microsoft is recalibrating its internal AI tools as costs climb, signaling a broader shift in how AI is priced into b...